Introduction
Children with sickle cell disease and other congenital hemolytic anemias sometimes develop temporary erythropoietic failure or aplastic crisis (1) (2) (3) . Aplastic crises follow seemingly nonspecific viral illnesses, and in some populations, may occur in seasonal epidemics (4) . Recent epidemiological studies have linked aplastic crises to infection with a specific viral agent, here termed serum parvovirus-like virus (SPLV)' (4, 5, 6) . During the acute phase of the illness of some patients, an antigen identified with SPLV has been detected and the virus seen by electron mi-croscopy. More frequently, an IgM class antibody to the virus has been detected by the time that the crisis is clinically evident and the first blood sample is taken (7) . In a previous study (8) , we have shown that serum containing SPLV inhibits hematopoietic colony formation in methylcellulose, with the strongest effect on the late erythroid progenitor, the CFU-E. The inhibitory effect of serum containing SPLV may be neutralized by serum containing antibody to the virus. Inhibitory effects were not dependent on complement nor affected by the presence of antihuman immunoglobulin, making it unlikely that the inhibition was mediated by immunological mechanisms. Fresh serum containing SPLV, which was obtained from a patient with an aplastic crisis associated with hereditary spherocytosis, was very potent, showing inhibition of erythroid colony formation by a l0-4 dilution of serum.
We now have further evidence that the inhibitory effect of serum from patients with transient aplastic crisis is due to infection of a hematopoietic progenitor cell with SPLV. We have investigated the physicochemical characteristics of this agent; the studies were necessarily preliminary given the limited amounts of virus-containing material currently available. Acutephase sera from other viral diseases have been screened for inhibitory activity in hematopoietic colony culture. In vitro experiments in which colony forming cells are physically isolated have identified the late erythroid progenitor, rather than an accessory cell required for hematopoiesis, as the target ofSPLV. A relationship between SPLV infection and other forms of marrow aplasia has been sought. (11) . By picking these colonies, a pure population of erythroid progenitors at the stage of CFU-E or later is obtained. Four to five bursts were picked by using a sterile tapered Pasteur pipette, pooled, and resuspended in 50 zd of IMDM-2% FCS. Half of this cell suspension was then incubated with SPLV-containing sera and the other half incubated with control sera. Methylcellulose culture medium as described above was added to each aliquot and plated. CFU-E-derived colonies, which were the progeny of these bursts, were then enumerated after a further 8 d of incubation.
Methods
Assays and source of serum parvovirus-like virus and antibody to SPL V. For the experiments described here, several sources of SPLVcontaining serum were utilized. Serum J.B. was obtained early in the course of an aplastic crisis of a child with sickle cell disease, and it was positive for SPLV antigen by radioimmunoassay (RIA) but did not contain antibody, using standard methods, to SPLV. Immunoprecipitation and electron microscopy, performed as described (12) showed particles ( Fig. 1) with the diameter and morphology associated with SPLV (13) . In tests for CFU-E inhibition, this serum preparation was of similar potency to a previously reported SPLV-containing serum, J.H. (8) , and inhibition of erythroid colony formation was detected up to a 10-4 dilution of serum (Fig. 2) . Sera Br I and Br II, from two of the original blood donors in whom SPLV antigen had been detected, were known to inhibit erythroid colony formation (8) .
Serum To test for the presence of inhibitory levels of interferon, 135 Mll of serum containing SPLV, which was diluted 10-2, was incubated with 2.7 ul goat immunoglobulin anti-human a-interferon (kindly provided by Dr. J. Hooks, National Institutes of Health) for 30 min at room temperature before addition to bone marrow cells as described above. Antibody added was sufficient to neutralize >100 U a-interferon.
Sucrose density gradient fractionation. SPLV was separated from other serum components by sedimentation through a sucrose density gradient. 100 Ml of a 1 in 2 dilution of the serum under test were applied 
Results
Separation ofSPLV. Sera from six individuals were sedimented through sucrose density gradients (Fig. 3 ). SPLV-con- (Fig. 3 A) . Inhibition, but to a lesser degree, was observed in the densest fractions of sera Br I and Br II (Fig. 3 B and C) ; these sera, from asymptomatic blood donors, had previously been repeatedly frozen and thawed. Inhibition was not present in immunoglobulin fractions, supporting an earlier observation that inhibition by SPLV-containing sera was not mediated by antibodies or complement. Inhibition was not observed in fractions of convalescent-phase sera (Fig. 3 D and E ) or in normal serum (Fig. 3 F) 10-2 dilutions of SPLV-containing serum were exposed to heat for the indicated time periods or to the enzymes and chemicals overnight at 4°C before addition ofcells and methylcellulose culture medium. Controls included normal sera treated in the same manner. Target cell of SPL V. Because SPLV affects CFU-E and BFU-E and does not have a major effect on CFU-C, it was reasonable to postulate that the target cell is an erythroid hematopoietic progenitor (8) . However, experiments done with total bone marrow cell suspension do not exclude the possibility ofinfection ofa helper cell, such as T lymphocyte or macrophage, required for erythroid differentiation. This was a special concern because animal parvoviruses are known to infect lymphocytes (18) and monocytes (19, 20 ). An experiment was devised that could directly test the target cell for SPLV. Mature erythroid colonies derived from BFU-E in vitro are composed ofthousands of normoblasts. If immature colonies, morphologically identifiable as derived from a burst-forming progenitor, are removed from primary tissue culture and suspended in new tissue culture media, multiple secondary colonies, which are similar in ap-pearance to colonies derived from CFU-E, are detected after replating. These secondary colonies arise from the population of late erythroid progenitors present in the immature burst, and at the time of plucking, grow in the absence of added helper or other bone marrow cells. As shown in Table III , exposure of such cells to SPLV-containing serum, either J.B. or Br II, before secondary plating decreased CFU-E colony formation in proportion to the inhibitory effects of partially purified virus. Serial observation by light microscopy showed that cells exposed to virus failed to multiply and lost their refractile appearance. These results are strong evidence that SPLV directly affects late erythroid progenitor cells and not an accessory cell required for erythroid differentiation.
SPLV and adult aplastic anemia. The relationship of SPLV infection to a variety of other bone marrow failure syndromes was investigated by testing for the presence of SPLV antigen and antibody to SPLV in the sera collected from patients with these disorders (Table IV) . As the first viral agent that has been identified as specifically toxic to human bone marrow cells in culture, SPLV is a potential etiologic agent in bone marrow disorders. However, free viral antigen was not detected in patients with adult aplastic anemia, pure red cell aplasia, or transient erythroblastopenia of childhood. In addition, in the series of Early-appearing bursts were individually removed from cultures and pooled in groups of five; half of each pool was exposed for 2 h to control serum and the other half exposed to SPLV-containing serum. Cells were then suspended in methylcellulose culture media and replated. n, total number of patients' sera available for assay. * IgM reactive at low levels and probably not specific. Antigen and antibody assays were performed as described in Methods.
In some cases, if tests for anti-SPLV IgG were negative, anti-SPLV IgM was not assayed. One serum sample from a patient with amegakaryocytic thrombocytopenia as found to be anti-SPLV IgG negative.
patients with adult aplastic anemia, the incidence of viral antibody was not higher than that reported in a normal European population. It is thus improbable that these diseases are, like transient aplastic crises of congenital hemolytic anemias, the expression of an acute infection with SPLV. However, the possibility that a proportion of adult bone marrow failures are due to delayed effects of SPLV infection has not been excluded.
Discussion
In an earlier publication (8) , we reported that SPLV-containing sera inhibits the formation of erythroid colonies in vitro, and this is consistent with epidemiologic evidence that links SPLV infection to the aplastic crisis of sickle cell disease. The profound effect ofSPLV or secondary colony formation by isolated erythroid bursts identified an erythroid progenitor as a target cell for the virus. The more pronounced effect, in vitro, of SPLV-containing sera on CFU-E compared with BFU-E may be a particular feature of the interaction of virus and its host cell, and possibly be related to the maturation of virusbinding sites like glycophorin (24) on developing erythroid cells. The increased sensitivity of CFU-E in comparison with BFU-E also may be related to the higher proportion of CFU-E that are actively proliferating (25) . Parvoviruses, the smallest DNAcontaining viruses, have a genome consisting of only 5,000 base pairs of nucleotide (26) , and parvovirus replication in the nucleus, therefore, is highly dependent on constituents provided by the cell during mitosis (27) . The difficulty of maintaining erythroid progenitors in suspension culture may also account for our inability to obtain functional virus from short-term suspension bone marrow cultures (unpublished observations).
The highly proliferative erythroid bone marrows of patients with chronic hemolytic diseases may be an especially good environment for parvovirus replication. Certainly, SPLV infection ofthese individuals interrupts hematopoiesis and causes sudden worsening of anemia. It is tempting to speculate that infection with SPLV or a related virus has led to outbreaks of temporary erythroid hypoplasia among hospitalized patients undergoing treatment for kwashiorkor (28) and that SPLV is responsible for hematodepressive virus disease described in Thailand (29) . Whether hematopoiesis is perturbed in otherwise healthy people infected with SPLV is a moot point as anemia has not been documented in these patients. SPLV antigen was not detected in the sera of patients with other forms of bone marrow failure, nor was the prevalence of antibody to SPLV increased in patients with adult aplastic anemia. These diseases cannot, therefore, follow the same pattern of acute SPLV infection associated with rapid development of aplasia that occurs in transient aplastic crises. However, acute SPLV infection and destruction of a stem cell earlier in the hematopoietic lineage than the CFU-E might not become clinically apparent until weeks or even months after the clearance of viral antigen from the blood, and this may be a mechanism leading to some forms of aplastic anemia. Chronic persistent or latent infection with a virus, such as SPLV, are other mechanisms by which infection might lead to bone marrow failure without the features of the acute disease seen in children with aplastic crisis. 
